{Reference Type}: Journal Article
{Title}: Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis.
{Author}: Barrero Hernández FJ;Romero Villarrubia A;Muñoz Fernández C;Guillén Martinez V;Aguilera Del Moral A;Barrios-López JM;Ramírez Rivas MA;Gálvez Muñoz AJ;Piñar Morales R;
{Journal}: J Pers Med
{Volume}: 14
{Issue}: 7
{Year}: 2024 Jun 27
{Factor}: 3.508
{DOI}: 10.3390/jpm14070692
{Abstract}: Serum neurofilament light chain (sNfL) levels have been proposed as a biomarker of the clinical activity, disability progression, and response to treatment of people with multiple sclerosis (PwMS); however, questions remain about its implementation in clinical practice. Ocrelizumab (OCR) has proven effective in improving clinical and radiological outcomes and reducing sNfL levels. This real-life study followed the sNfL levels of 30 PwMS treated for 12 months with OCR and evaluated the usefulness of this biomarker for their short-term prognosis, considering expanded disability status scale (EDSS), annualized relapse rate (ARR), radiological activity, and NEDA-3 values. OCR reduced ARR in 83% of PwMS and radiological activity in 80%. EDSS was maintained, while NEDA-3 was achieved in 70% at 12 months. OCR produced an early reduction in sNfL levels (at 3 months). At baseline, greater MRI-evaluated radiological activity was associated with higher sNfL levels. sNfL levels over the first 12 months of treatment did not predict a suboptimal response or sustained control of the disease. Longer-term studies are needed to explore the predictive usefulness of sNfL levels in PwMS treated with high-efficacy drugs.